EPISTOP试验:结节性硬化症婴儿癫痫的预防性治疗
EPISTOP为多中心临床试验,94例无癫痫发作史的结节性硬化症(TSC)婴儿每月接受视频脑电图监测,在出现癫痫样脑电异常后分别接受预防性或常规氨己烯酸治疗。预防性治疗显著延长至首次临床发作的时间,并降低临床癫痫、药物难治性癫痫及婴儿痉挛的风险,未发现相关不良事件。
要点
- 对TSC婴儿监测到发作前癫痫样脑电异常即可启动预防性氨己烯酸治疗。
- 预防性治疗延迟首次临床发作并降低药物难治性癫痫与婴儿痉挛风险。
- 预防性氨己烯酸治疗未见相关不良事件。
核心结论
- 预防性氨己烯酸治疗安全,并改变TSC患儿癫痫的自然史,降低癫痫风险与严重程度。
研究设计与样本
- EPISTOP为多中心研究,94例无惊厥史的TSC婴儿接受每月视频脑电图随访。
- 6个中心按1:1随机分配进入随机对照试验(RCT),4个中心治疗分配固定,为开放标签试验(OLT)。
- 研究对象随访至2岁,主要终点为至首次临床发作的时间。
主要发现
- 54例在发作前检出癫痫样脑电异常,其中27例进入RCT、27例进入OLT。
- 至首次临床发作时间:RCT预防性364天(95%CI=223-535)vs常规124天(95%CI=33-149)。
- 至首次临床发作时间:OLT预防性426天(95%CI=258-628)vs常规106天(95%CI=11-149)。
- 24个月 pooled 分析:预防性治疗降低临床癫痫风险(OR=0.21,p=0.032)、药物难治性癫痫(OR=0.23,p=0.022)及婴儿痉挛(OR=0,p<0.001)。
- 未见与预防性治疗相关的不良事件。
关键数值与推荐
- TSC婴儿无惊厥史者以每月视频脑电图监测,检出癫痫样异常后启动预防性氨己烯酸治疗。
临床怎么用
- 对TSC婴儿可考虑规律视频脑电图监测,并在发作前出现癫痫样异常时启动预防性氨己烯酸治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Epilepsy develops in 70 to 90% of children with tuberous sclerosis complex (TSC) and is often resistant to medication. Recently, the concept of preventive antiepileptic treatment to modify the natural history of epilepsy has been proposed. EPISTOP was a clinical trial designed to compare preventive versus conventional antiepileptic treatment in TSC infants. METHODS: In this multicenter study, 94 infants with TSC without seizure history were followed with monthly video electroencephalography (EEG), and received vigabatrin either as conventional antiepileptic treatment, started after the first electrographic or clinical seizure, or preventively when epileptiform EEG activity before seizures was detected. At 6 sites, subjects were randomly allocated to treatment in a 1:1 ratio in a randomized controlled trial (RCT). At 4 sites, treatment allocation was fixed; this was denoted an open-label trial (OLT). Subjects were followed until 2 years of age. The primary endpoint was the time to first clinical seizure. RESULTS: In 54 subjects, epileptiform EEG abnormalities were identified before seizures. Twenty-seven were included in the RCT and 27 in the OLT. The time to the first clinical seizure was significantly longer with preventive than conventional treatment [RCT: 364 days (95% confidence interval [CI] = 223-535) vs 124 days (95% CI = 33-149); OLT: 426 days (95% CI = 258-628) vs 106 days (95% CI = 11-149)]. At 24 months, our pooled analysis showed preventive treatment reduced the risk of clinical seizures (odds ratio [OR] = 0.21, p = 0.032), drug-resistant epilepsy (OR = 0.23, p = 0.022), and infantile spasms (OR = 0, p < 0.001). No adverse events related to preventive treatment were noted. INTERPRETATION: Preventive treatment with vigabatrin was safe and modified the natural history of seizures in TSC, reducing the risk and severity of epilepsy. ANN NEUROL 2021;89:304-314.
引用
- Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. Ann Neurol. 2020. PMID: 33180985. doi:10.1002/ana.25956
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。